Paul Tudor Jones's LGND Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 15.75 M shares of Ligand Pharmaceuticals Incorporated (LGND) worth $17.7 M, representing 0.03% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in LGND, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 15.74 M shares. Largest reduction occurred in Q1 2019, reducing 19,045 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +11,700 | New Buy | 11,700 | $43.25 |
| Q4 2013 | -11,700 | Sold Out | 11,700 | $0.00 |
| Q1 2014 | +4,252 | New Buy | 4,252 | $67.26 |
| Q2 2014 | -4,252 | Sold Out | 4,252 | $0.00 |
| Q3 2014 | +5,200 | New Buy | 5,200 | $46.92 |
| Q4 2014 | -5,200 | Sold Out | 5,200 | $0.00 |
| Q4 2015 | +2,468 | New Buy | 2,468 | $108.59 |
| Q1 2016 | +1,432 | Add 58.02% | 3,900 | $107.18 |
| Q2 2016 | +500 | Add 12.82% | 4,400 | $119.32 |
| Q3 2016 | -2,100 | Reduce 47.73% | 2,300 | $102.17 |
| Q4 2016 | -2,300 | Sold Out | 2,300 | $0.00 |
| Q1 2018 | +1,605 | New Buy | 1,605 | $165.11 |
| Q2 2018 | +3,719 | Add 231.71% | 5,324 | $207.18 |
| Q3 2018 | -5,324 | Sold Out | 5,324 | $0.00 |
| Q4 2018 | +30,432 | New Buy | 30,432 | $135.71 |
| Q1 2019 | -19,045 | Reduce 62.58% | 11,387 | $125.67 |
| Q2 2019 | +6,172 | Add 54.20% | 17,559 | $114.13 |
| Q3 2019 | -15,223 | Reduce 86.70% | 2,336 | $99.74 |
| Q4 2019 | +3,451 | Add 147.73% | 5,787 | $104.37 |
| Q1 2020 | -5,787 | Sold Out | 5,787 | $0.00 |
| Q3 2020 | +5,391 | New Buy | 5,391 | $95.34 |
| Q4 2020 | +8,747 | Add 162.25% | 14,138 | $99.45 |
| Q1 2021 | -10,805 | Reduce 76.43% | 3,333 | $152.42 |
| Q2 2021 | -3,333 | Sold Out | 3,333 | $0.00 |
| Q4 2021 | +3,313 | New Buy | 3,313 | $154.54 |
| Q1 2022 | -3,313 | Sold Out | 3,313 | $0.00 |
| Q4 2022 | +9,944 | New Buy | 9,944 | $0.07 |
| Q1 2023 | -4,322 | Reduce 43.46% | 5,622 | $0.07 |
| Q2 2023 | -5,622 | Sold Out | 5,622 | $0.00 |
| Q3 2025 | +15.75 M | New Buy | 15.75 M | $1.12 |
Paul Tudor Jones's Ligand Pharmaceuticals Incorporated Investment FAQs
Paul Tudor Jones first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q3 2013, acquiring 11,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Ligand Pharmaceuticals Incorporated (LGND) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q3 2025, adding 15,750,000 shares worth $17.7 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 15,750,000 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $17.7 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.03% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 15,750,000 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.